Reductions in glycaemia and weight with once-weekly dosing of LY2189265, a long-acting glucagon-like peptide 1 (GLP-1) analogue in patients with type 2 diabetes mellitus

被引:0
|
作者
Hardy, T. A. [1 ]
Barrington, P. [2 ]
Chien, J. [1 ]
Showalter, H. [1 ]
Schneck, K. [1 ]
Cui, S.
Tibaldi, F. [3 ]
Ellis, B. [1 ]
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Windlesham, Surrey, England
[3] GSK Biol, Rixensart, Belgium
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
731
引用
收藏
页码:S286 / S286
页数:1
相关论文
共 50 条
  • [1] Reductions in Glycemia and Weight with Once Weekly Dosing of LY2189265, a Long-Acting Glucagon-Like Peptide 1 (GLP-1) Analog in Patients with Type 2 Diabetes Mellitus
    Barrington, Philip
    Hardy, Thomas A.
    Chien, Jenny Y.
    Showalter, H. D. Hollins
    Schneck, Karen B.
    Cui, Sherry
    Tibaldi, Fabian
    Ellis, Bernice
    DIABETES, 2009, 58 : A42 - A42
  • [2] LY2189265, a Long-Acting Glucagon-Like Peptide 1 (GLP-1) Analog, Does Not Affect Gastric Emptying of Acetaminophen after Multiple Dosing in Healthy Subjects
    Chien, Jenny Y.
    Cui, Sherry
    Chaudhary, Archana
    Loghin, Corina
    DIABETES, 2010, 59 : A164 - A164
  • [3] Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
    Glaesner, Wolfgang
    Vick, Andrew Mark
    Millican, Rohn
    Ellis, Bernice
    Tschang, Sheng-Hung
    Tian, Yu
    Bokvist, Krister
    Brenner, Martin
    Koester, Anja
    Porksen, Niels
    Etgen, Garret
    Bumol, Tom
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2010, 26 (04) : 287 - 296
  • [4] A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
    Barrington, P.
    Chien, J. Y.
    Showalter, H. D. H.
    Schneck, K.
    Cui, S.
    Tibaldi, F.
    Ellis, B.
    Hardy, T. A.
    DIABETES OBESITY & METABOLISM, 2011, 13 (05): : 426 - 433
  • [5] Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
    Lau, Jesper
    Bloch, Paw
    Schaffer, Lauge
    Pettersson, Ingrid
    Spetzler, Jane
    Kofoed, Jacob
    Madsen, Kjeld
    Knudsen, Lotte Bjerre
    McGuire, James
    Steensgaard, Dorte Bjerre
    Strauss, Holger Martin
    Gram, Dorte X.
    Knudsen, Sanne Moller
    Nielsen, Flemming Seier
    Thygesen, Peter
    Reedtz-Runge, Steffen
    Kruse, Thomas
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (18) : 7370 - 7380
  • [6] Safety, Tolerability, Pharmacokinetics, and Insulinotropic Activity of Single Subcutaneous Doses of LY2189265, a Long-Acting Glucagon-Like Peptide 1 (GLP-1) Analog in Healthy Subjects
    Barrington, Philip
    Chien, Jenny Y.
    Tibaldi, Fabian
    Showalter, H. D. Hollilns
    Schneck, Karen B.
    Ellis, Bernice
    DIABETES, 2009, 58 : A157 - A157
  • [7] The effect of LY2189265 (GLP-1 analogue) once weekly on HbA1c and beta cell function in uncontrolled type 2 diabetes mellitus: the EGO study analysis
    Umpierrez, G.
    Blevins, T.
    Rosenstock, J.
    Cheng, C.
    Bastyr, E.
    Anderson, J.
    DIABETOLOGIA, 2009, 52 : S59 - S59
  • [8] Safety, tolerability, pharmacokinetics, and insulinotropic activity of single subcutaneous doses of LY2189265, a long-acting glucagon-like peptide 1 analogue in healthy subjects
    Barrington, P.
    Chien, J.
    Tibaldi, F.
    Showalter, H.
    Schneck, K.
    Ellis, B.
    DIABETOLOGIA, 2009, 52 : S307 - S308
  • [9] LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects
    Barrington, P.
    Chien, J. Y.
    Tibaldi, F.
    Showalter, H. D. H.
    Schneck, K.
    Ellis, B.
    DIABETES OBESITY & METABOLISM, 2011, 13 (05): : 434 - 438
  • [10] In Vivo Effect of Semaglutide in Pigs Supports Its Potential as a Long-Acting GLP-1 Analogue for Once-Weekly Dosing
    Rolin, Bidda
    Larsen, Marianne O.
    Christoffersen, Berit O.
    Lau, Jesper
    Knudsen, Lotte B.
    DIABETES, 2015, 64 : A287 - A287